Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899604 | 0.81 | TGFBR1 (0.46) | TGFBR1MAPK14MTORPIM1 | |
| SCHEMBL18005295 | 0.81 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL5138951 | 0.81 | TGFBR1 (0.67) | TGFBR1MAPK14MTOR | |
| SCHEMBL25084906 | 0.80 | TGFBR1 (0.48) | TGFBR1MAPK14PIM1PIM3PIM2 | |
| SCHEMBL25084907 | 0.78 | TGFBR1 (0.44) | TGFBR1MAPK14PIM1PIM3PIM2 | |
| SCHEMBL30155846 | 0.78 | TGFBR1 (0.44) | TGFBR1MAPK14PIM1PIM3PIM2 | |
| SCHEMBL5202460 | 0.77 | ALDH1A1 (0.41) | TGFBR1 | |
| SCHEMBL4902499 | 0.76 | TGFBR1 (0.46) | TGFBR1MAPK14MTORPIM1PIM3 | |
| SCHEMBL29796507 | 0.76 | TGFBR1 (0.42) | TGFBR1MAPK14PIM1PIM3PIM2 | |
| SCHEMBL23389539 | 0.76 | TGFBR1 (0.42) | TGFBR1MAPK14PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | claimed |
| JP-2006517592-A | — | — | 2006-07-27 | — | — | JP | claimed |
| CN-1770980-A | Pyrazoles and methods of making and using the same | BIOGEN IDEC INC (US) | 2006-05-10 | — | — | CN | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| CN-1770980-A | Pyrazoles and methods of making and using the same | BIOGEN IDEC INC (US) | 2006-05-10 | — | — | CN | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | TGFBR1 26/4885MAPK14 1842/4885MTOR 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.